Patients, der fik pioglitazon opnåede en middelreduktion i HbA1c på 0, 45% sammenlignet med dem, der fortsatte med insulin alene, og der var en reduktion af insulindosis i den pioglitazonbehandlede gruppe.
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.